OSUR

Business Context and Reporting Period

Company: OraSure Technologies, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2001
Business Overview: OraSure develops, manufactures, and markets oral fluid specimen collection devices and diagnostic products, including immunoassays and rapid tests for infectious diseases (HIV), substance abuse, and insurance risk assessment. The company operates in the United States and internationally, selling to government agencies, laboratories, and distributors.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 13% to $32.6 million. Excluding the discontinued Serum Western Blot product ($1.6 million in 2000), revenue growth was approximately 20%.
• Market Segment Shifts:
  • Insurance Risk Assessment: Declined 20% to $11.7 million due to the discontinuation of the Serum Western Blot test, inventory consolidation by major customer LabOne, Inc., and lower urine assay sales.
  • Substance Abuse Testing: Increased 119% to $7.0 million, driven by the market penetration of the Intercept(R) drug testing service.
  • Infectious Disease Testing: Increased 67% to $5.8 million, attributed to OraSure(R) HIV-1 test penetration and OraQuick(R) shipments to Africa.
• Profitability Improvement: Net loss narrowed significantly from $12.7 million in 2000 to $3.7 million in 2001. This was driven by a 10% reduction in R&D expenses, the absence of $7.6 million in merger-related expenses (incurred in 2000), and improved gross margins.
• Liquidity: Cash and cash equivalents decreased by approximately $4.9 million, primarily due to the net loss, increased inventory levels (specifically OraQuick(R) raw materials), and loan repayments.

Guidance, Outlook, and Risks

• Outlook: Management expects revenues for the first two quarters of 2002 to be roughly comparable to the same periods in 2001. The company anticipates increased capital expenditures in 2002 for UPlink(TM) manufacturing equipment and facility fit-outs.
• Workforce Reduction: In Q1 2002, the company implemented a 10% reduction in force and terminated certain development projects (including a syphilis test) due to lower-than-anticipated sales levels in 2001.
• Regulatory Status:
  • OraQuick(R) HIV: Application for pre-market approval (PMA) for whole blood testing submitted; oral fluid application expected in 2002.
  • UPlink(TM): FDA requested additional data for the analyzer and drug assays; resubmission expected in 2002.
  • CE Mark: Products require CE mark approval by December 31, 2003, to continue sales in the European Community.
• Key Risks:
  • Customer Concentration: LabOne, Inc. (including acquired Osborne Group) accounted for 29% of 2001 revenues. Further inventory consolidation by this customer could materially impact sales.
  • Patent Issues: Potential restrictions on selling OraQuick(R) in certain markets due to HIV-2 and lateral flow patent rights held by third parties.
  • Regulatory Compliance: History of FDA observations regarding Quality System Regulations (QSR) at the Oregon facility; although the Serum Western Blot product was discontinued, ongoing compliance is critical for other products.
  • Liquidity: The company has a history of losses and an accumulated deficit of $126.1 million. Future financing may be required to fund operations and expansion.

Investor Verification Checklist

• Customer Concentration: Verify the stability of the relationship with LabOne, Inc., which represents nearly 30% of revenue, and assess the risk of further inventory drawdowns.
• Regulatory Approvals: Monitor the status of FDA approvals for the OraQuick(R) rapid HIV test and the UPlink(TM) drug detection system, as commercialization depends on these clearances.
• Inventory Valuation: Review the $0.6 million inventory reserve recorded in Q4 2001 for OraQuick(R) products and assess the risk of future write-offs given the terminated African distribution agreement.
• Patent Licensing: Confirm the company's ability to secure necessary licenses for HIV-2 and lateral flow technologies to ensure global market access for OraQuick(R).
• Cash Burn Rate: Evaluate the sufficiency of the $15.2 million in cash and short-term investments against the projected operating losses and capital expenditure requirements for 2002.